BioXcel Therapeutics (BTAI) Return on Capital Employed (2018 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Return on Capital Employed of 325.86% for Q1 2026, up 73792.0% year-over-year from N/an in Q1 2025, and down 41.42% quarter-over-quarter from 556.23% in Q4 2025.
BioXcel Therapeutics (BTAI) Return on Capital Employed (2018 - 2026) Analysis & Trends
BioXcel Therapeutics' Return on Capital Employed history runs 9 years deep, the most recent figure standing at 325.86% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 73792.0% year-over-year to 325.86%; the TTM figure through Mar 2026 stood at 325.86% (up 73792.0% YoY), while the FY2025 annual figure was 410.29%, up 60931.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 325.86%, down from 556.23% in the prior quarter.
- The five-year high for Return on Capital Employed was 4316.81% in Q2 2025, with the low at 412.06% in Q1 2025.
- The 5-year median for Return on Capital Employed is 109.23% (2023), against an average of 272.95%.
- The sharpest annual moves came in 2023 and 2025: Return on Capital Employed sank 20426 bps in 2023, then surged 455212 bps in 2025.
- BioXcel Therapeutics' Return on Capital Employed stood at 82.96% in 2022, then slumped by 246 bps to 287.22% in 2023, then decreased by 9 bps to 314.49% in 2024, then jumped by 277 bps to 556.23% in 2025, then tumbled by 41 bps to 325.86% in 2026.
- Business Quant data shows BTAI's Return on Capital Employed at 325.86% in Q1 2026, 556.23% in Q4 2025, and 2015.99% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | BioXcel Therapeutics | 24.24 Mn | 24.24 Mn | 160,000.00 | 42.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.49% |
| Mar 31, 2026 | 325.86% |
| Dec 31, 2025 | 556.23% |
| Sep 30, 2025 | 2,015.99% |
| Jun 30, 2025 | 4,316.81% |
| Mar 31, 2025 | -412.06% |
| Dec 31, 2024 | -314.49% |
| Sep 30, 2024 | -242.44% |
| Jun 30, 2024 | -235.31% |
| Mar 31, 2024 | -311.08% |
| Dec 31, 2023 | -287.22% |
| Sep 30, 2023 | -253.27% |
| Jun 30, 2023 | -155.95% |
| Mar 31, 2023 | -109.23% |
| Dec 31, 2022 | -82.96% |
| Sep 30, 2022 | -59.55% |
| Jun 30, 2022 | -57.58% |
| Mar 31, 2022 | -53.54% |
| Dec 31, 2021 | -45.75% |
| Sep 30, 2021 | -39.71% |